Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4

Howard J. Burt, Henry Pertinez, Carolina Säll, Claire Collins, Ruth Hyland, J. Brian Houston and Aleksandra Galetin
Drug Metabolism and Disposition September 2012, 40 (9) 1658-1667; DOI: https://doi.org/10.1124/dmd.112.046078
Howard J. Burt
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Pertinez
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Säll
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Collins
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Hyland
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Brian Houston
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aleksandra Galetin
Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 40 no. 9 1658-1667
DOI 
https://doi.org/10.1124/dmd.112.046078
PubMed 
22621802

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received April 5, 2012
  • Accepted May 23, 2012
  • Published online August 17, 2012.

Article Versions

  • Earlier version (May 23, 2012 - 08:52).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Howard J. Burt1,
  2. Henry Pertinez,
  3. Carolina Säll,
  4. Claire Collins,
  5. Ruth Hyland,
  6. J. Brian Houston and
  7. Aleksandra Galetin
  1. Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (H.J.B., H.P., C.S., J.B.H., A.G.); and Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (C.C., R.H.)
  1. Address correspondence to:
    Dr. Aleksandra Galetin, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK. E-mail: Aleksandra.Galetin{at}manchester.ac.uk
  • ↵1 Current affiliation: Simcyp Limited, Sheffield, United Kingdom.

View Full Text

Statistics from Altmetric.com

Article usage

Article usage: May 2012 to May 2022

AbstractFullPdf
May 2012301071
Jun 2012166066
Jul 2012101053
Aug 201276233158
Sep 201264020106
Oct 20122061439
Nov 20121331733
Dec 2012118919
Jan 20131193024
Feb 2013102721
Mar 201366819
Apr 201367910
May 2013621322
Jun 201336912
Jul 20135569
Aug 20134998
Sep 2013962722
Oct 2013542415
Nov 2013341722
Dec 2013211318
Jan 2014181819
Feb 2014401420
Mar 2014291212
Apr 2014331919
May 2014253118
Jun 2014281622
Jul 2014352114
Aug 201414148
Sep 2014292320
Oct 2014221419
Nov 2014132113
Dec 2014122011
Jan 201512216
Feb 201517199
Mar 201521266
Apr 2015222219
May 2015151217
Jun 2015161813
Jul 2015252216
Aug 2015132612
Sep 201524178
Oct 2015181414
Nov 201581713
Dec 2015161819
Jan 2016231019
Feb 201671712
Mar 201614926
Apr 20166215
May 201681010
Jun 2016111115
Jul 2016141122
Aug 2016211221
Sep 2016111526
Oct 201682521
Nov 201664217
Dec 201642819
Jan 201712513
Feb 201702314
Mar 201714122
Apr 201702915
May 201702410
Jun 2017044
Jul 20171154
Aug 201741714
Sep 201712015
Oct 201702517
Nov 2017013212
Dec 2017153511
Jan 201804539
Feb 2018527423
Mar 201861828
Apr 201809715
May 20180588
Jun 201824111
Jul 20180205
Aug 20181226
Sep 20181204
Oct 201808314
Nov 2018110716
Dec 2018107268
Jan 20199148
Feb 201988411
Mar 20192142
Apr 201929210
May 20191376
Jun 20191424
Jul 20191406
Aug 20191358
Sep 20191335
Oct 201940515
Nov 20192502
Dec 20193546
Jan 202024212
Feb 20201744
Mar 20202094
Apr 20201312
May 202018112
Jun 20201544
Jul 20201024
Aug 20207210
Sep 20201036
Oct 20201036
Nov 202022310
Dec 20202053
Jan 20212459
Feb 202149119
Mar 20212451
Apr 20213147
May 20214267
Jun 20213255
Jul 2021926
Aug 202112127
Sep 20211244
Oct 2021831
Nov 202126210
Dec 20212333
Jan 20222433
Feb 202228412
Mar 2022331
Apr 20221299
May 20221316

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 40 (9)
Drug Metabolism and Disposition
Vol. 40, Issue 9
1 Sep 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

PROGRESS CURVE ASSESSMENT OF TIME-DEPENDENT INHIBITION

Howard J. Burt, Henry Pertinez, Carolina Säll, Claire Collins, Ruth Hyland, J. Brian Houston and Aleksandra Galetin
Drug Metabolism and Disposition September 1, 2012, 40 (9) 1658-1667; DOI: https://doi.org/10.1124/dmd.112.046078

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

PROGRESS CURVE ASSESSMENT OF TIME-DEPENDENT INHIBITION

Howard J. Burt, Henry Pertinez, Carolina Säll, Claire Collins, Ruth Hyland, J. Brian Houston and Aleksandra Galetin
Drug Metabolism and Disposition September 1, 2012, 40 (9) 1658-1667; DOI: https://doi.org/10.1124/dmd.112.046078
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Determination of Acyl-, O-, and N-Glucuronide
  • TMDD Affects PK of IL-10 Fc-fusion Proteins
  • Uptake as the RDS in Pevonedistat Hepatic Clearance
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics